Oosterlinck W, Kurth K H, Schröder F, Bultinck J, Hammond B, Sylvester R
Department of Urology, University Hospital, Gent, Belgium.
J Urol. 1993 Apr;149(4):749-52. doi: 10.1016/s0022-5347(17)36198-0.
A total of 431 eligible patients with solitary, primary or recurrent stages Ta and T1 transitional cell carcinoma of the bladder was included in a randomized multicenter trial to compare a single intravesical instillation of 80 mg. epirubicin with water given immediately after resection, with respect to the disease-free interval and recurrence rate. The interval to initial recurrence was significantly better in favor of the epirubicin group. After a mean followup of 2 years it became evident that the recurrence rate after a single epirubicin instillation was decreased by nearly half with the same trend being found in all subgroups examined. Toxicity was mainly restricted to bladder irritation in plus or minus 10% of the cases. Pathology review brought considerable changes in T category from stages T1 to Ta (53%). Changes in grade were less pronounced but nevertheless important.
共有431例符合条件的膀胱Ta期和T1期单发、原发性或复发性移行细胞癌患者被纳入一项随机多中心试验，以比较在切除术后立即膀胱内单次灌注80mg表柔比星与灌注水在无病间期和复发率方面的差异。首次复发的间期明显有利于表柔比星组。平均随访2年后发现，单次表柔比星灌注后的复发率降低了近一半，在所检查的所有亚组中均发现相同趋势。毒性主要局限于约10%的病例出现膀胱刺激。病理复查使T分期从T1期到Ta期有相当大的变化（53%）。分级变化不太明显，但仍然很重要。
